###begin article-title 0
###xml 114 118 110 114 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
Proteinase-activated receptor-2 mediated inhibition of TNFalpha-stimulated JNK activation - A novel paradigm for Gq/11 linked GPCRs
###end article-title 0
###begin p 1
This document may be redistributed and reused, subject to .
###end p 1
###begin title 2
Abstract
###end title 2
###begin p 3
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 120 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 204 205 200 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 549 550 533 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 620 621 604 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 687 688 671 672 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1066 1070 1046 1050 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 1106 1107 1086 1087 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1146 1147 1126 1127 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1312 1313 1292 1293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1400 1404 1380 1384 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
In this study we examined the potential for PAR2 and TNFalpha to synergise at the level of MAP kinase signalling in PAR2 expressing NCTC2544 cells. However, to our surprise we found that activation of PAR2 by trypsin or the specific activating peptide SLIGKV-OH strongly inhibited both the phosphorylation and activity of JNK. In contrast neither p38 MAP kinase nor ERK activation was affected although TNFalpha stimulated IkappaBalpha loss was partially reversed. The inhibitory effect was not observed in parental cells nor in cells expressing PAR4, however inhibition was reversed by pre-incubation with the novel PAR2 antagonist K14585, suggesting that the effect is specific for PAR2 activation. SLIGKV-OH was found to be more potent in inhibiting TNFalpha-induced JNK activation than in stimulating JNK alone, suggesting agonist-directed signalling. The PKC activator PMA, also mimicked the inhibitory effect of SLIGKV-OH, and the effects of both agents were reversed by pre-treatment with the PKC inhibitor, GF109203X. Furthermore, incubation with the novel Gq/11 inhibitor YM25480 also reversed PAR2 mediated inhibition. Activation of PAR2 was found to disrupt TNFR1 binding to RIP and TRADD and this was reversed by both GF109203X and YM25480. A similar mode of inhibition observed in HUVECs through PAR2 or P2Y2 receptors demonstrates the potential of a novel paradigm for GPCRs linked to Gq/11, in mediating inhibition of TNFalpha-stimulated JNK activation. This has important implications in assessing the role of GPCRs in inflammation and other conditions.
###end p 3
###begin title 4
Abbreviations
###end title 4
###begin title 5
Keywords
###end title 5
###begin title 6
Introduction
###end title 6
###begin p 7
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 141 142 141 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 142 145 142 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib1" ref-type="bibr">[1]</xref>
###xml 230 235 230 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib2 bib3 bib4" ref-type="bibr">[2&#8211;4]</xref>
###xml 259 260 259 260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 368 373 368 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib5 bib6" ref-type="bibr">[5,6]</xref>
###xml 388 391 388 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib7" ref-type="bibr">[7]</xref>
###xml 508 509 508 509 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 595 601 595 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib9 bib10" ref-type="bibr">[8&#8211;10]</xref>
###xml 663 670 663 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib11 bib12" ref-type="bibr">[11,12]</xref>
###xml 757 758 757 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 771 772 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 884 888 884 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib13" ref-type="bibr">[13]</xref>
###xml 913 914 913 914 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1024 1028 1024 1028 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib14" ref-type="bibr">[14]</xref>
Proteinase-activated receptor-2 (PAR2), is a member of the G-protein coupled receptor (GPCR) subfamily typified by the thrombin receptor, PAR1[1]. The receptor is activated by serine proteinases, most notably trypsin and tryptase [2-4]. Extensive study of PAR2 has revealed the receptor to be of potential importance in the functional control of blood vessel function [5,6], lung patency [7] and gastrointestinal tract motility and ion transport. A number of additional studies have implicated a role for PAR2 in several disease states including chronic arthritis, inflammatory pain and colitis [8-10] and in skin disorders such as type IV and contact dermatitis [11,12]. However, additional evidence also supports an anti-inflammatory role, for example PAR2 mediates PGI2-dependent relaxation of vessels which counteracts pro-inflammatory events such as ischaemia-reperfusion injury [13], and in the airways, PAR2 activation evokes an epithelium and prostanoid-dependent relaxation in isolated bronchi from several species [14]. What molecular mechanisms mediate such duality of function is unknown.
###end p 7
###begin p 8
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 193 197 193 197 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib15" ref-type="bibr">[15]</xref>
###xml 247 251 247 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib16" ref-type="bibr">[16]</xref>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 467 474 463 470 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17 bib18" ref-type="bibr">[17,18]</xref>
###xml 479 480 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 598 602 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">[17]</xref>
###xml 663 670 659 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib19 bib20" ref-type="bibr">[19,20]</xref>
###xml 604 609 <span type="species:ncbi:9606">human</span>
###xml 633 636 <span type="species:ncbi:10116">rat</span>
The cellular actions of PAR2 have been shown to be mediated through the activation of a number of key signalling pathways. This includes the mitogen-activated protein kinases, principally ERKs [15] mediated via interaction with the beta arrestins [16]. PAR2 also couples to a number of signalling pathways usually stimulated strongly by cytokines, such as the nuclear factor kappa B (NFkappaB) pathway and the stress-activated protein kinases, p38 map kinase and JNK [17,18]. PAR2 coupling to the stress-activated protein kinases, JNK, and p38 MAP kinase has been demonstrated in transfected cells [17], human blood eosinophils, and rat pancreatic stellate cells [19,20], however the exact mechanisms involved remain unclear.
###end p 8
###begin p 9
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 170 177 163 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib21 bib22 bib23" ref-type="bibr">[21&#8211;23]</xref>
###xml 292 293 281 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 315 322 304 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib24 bib25" ref-type="bibr">[24,25]</xref>
###xml 360 361 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 406 410 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
###xml 444 445 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 524 525 513 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 687 688 672 673 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 765 766 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 923 927 900 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
Previous studies have demonstrated that activation of PAR2 leads to the release of several potent pro-inflammatory mediators, including IL-6, IL-8, TNFalpha and IL-1beta [21-23], resulting in enhanced inflammatory responses. TNFalpha pre-treatment has been shown to up-regulate functional PAR2 in endothelial cells [24,25], whilst recent studies have shown PAR2 to interact with TLR-4 signalling via myd88 [26], suggesting the potential for PAR2 to enhance inflammation. Thus, in this study we examined the potential for PAR2 to synergize with TNFalpha in the activation of pro-inflammatory signalling responses such as JNK and p38 MAP kinase in a cell line (clone G) expressing both PAR2 and TNFR1 receptors. However to our surprise we found that activation of PAR2 was associated with a marked inhibition in TNFalpha stimulated JNK phosphorylation and to a lesser extent NFkappaB which was mediated by activation of the Gq/11 pathway via the activation of PKC and had a site of inhibition at the coupling of TNFR1 to receptor associated proteins. This extends a previous study from our laboratory examining purinergic P2Y receptors and suggests the existence of a novel paradigm for GPCR signalling, the inhibition of TNFalpha-stimulated JNK.
###end p 9
###begin title 10
Material and methods
###end title 10
###begin title 11
Reagents
###end title 11
###begin p 12
###xml 590 591 574 575 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 640 641 624 625 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
All materials used were of the highest commercial grade available and were purchased from Sigma (Dorset, UK) or Calbiochem (Nottingham, UK), unless otherwise stated. The PKC inhibitor, GF109203X, was obtained from Calbiochem (San Diego, CA, USA). Antibodies raised against phosphorylated forms of JNK and p38 MAP kinase were purchased from Biosource (CA, USA). Anti-IkappaBalpha, anti-JNK and p38 MAP kinase antibodies were obtained from Santa Cruz Biotechnology (CA, USA). Meanwhile, tumour necrosis factor-alpha (TNFalpha) was purchased from Insight Biotechnology (Middlesex, UK). The PAR2 activating peptide 2f-LIGKV-OH and the novel PAR2 peptide mimetic K-14585 were kind gifts from the Kowa Company Ltd. (Tokyo, Japan). The YM-254890 compound was a kind gift of Astellas Pharma. Inc, Japan.
###end p 12
###begin title 13
Cell culture
###end title 13
###begin p 14
###xml 248 249 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 527 531 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib27" ref-type="bibr">[27]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 114 118 <span type="species:ncbi:9913">calf</span>
###xml 239 244 <span type="species:ncbi:9606">human</span>
###xml 444 449 <span type="species:ncbi:9606">human</span>
###xml 621 625 <span type="species:ncbi:9913">calf</span>
Human skin epithelial cells NCTC2544 were maintained in M199 medium with Earl's salt supplement, 10% (v/v) foetal calf serum, L-glutamine (27 microg/ml), penicillin (250 U/ml), and streptomycin (25 mg/ml). NCTC2544 cells stably expressing human PAR2 (clone G) were maintained in complete M199 medium containing 400 mug/ml of Geneticin for selection pressure and passaged using Versene (2% EDTA/PBS). EAhy-926 cells were produced by hybridizing human umbilical vein endothelial cells (HUVECs) with the epithelial cell line A549 [27] and maintained in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 10% foetal calf serum (FCS), hypoxanthine/aminopterin/thymidine (HAT supplement), penicillin (250 U/ml) and streptomycin (25 mg/ml), and cells were passaged using Versene.
###end p 14
###begin p 15
###xml 453 454 453 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 135 141 <span type="species:ncbi:9913">bovine</span>
HUVECs were grown in endothelial basal media, supplemented with endothelial growth media (EGM-2) containing single aliquots (2% foetal bovine serum, 0.2 ml hydrocortisone, 2 ml hFGF-B, 0.5 ml VEGF, 0.5 ml R3-insulin like growth factor-1, 0.5 ml ascorbic acid, 0.5 ml hEGF, 0.5 ml GA 1000, and 0.5 ml heparin) purchased from Cambrex. All experiments were performed between passages 3 and 7. All cells were kept in a humidified atmosphere containing 5% CO2 at 37 degreesC.
###end p 15
###begin title 16
Western blotting
###end title 16
###begin p 17
Proteins were separated by 10% SDS-PAGE and transferred onto nitrocellulose. The membranes were blocked for non-specific binding for 2 h in 2% BSA (w/v) diluted in NATT buffer (50 mM Tris-HCl, 150 mM NaCl, 0.2% (v/v) Tween-20). The blots were then incubated overnight with 50 ng/ml primary antibody diluted in 0.2% BSA (w/v) in NATT buffer. The blots were washed with NATT buffer for 90 min and incubated with HRP-conjugated secondary antibody (20 ng/ml in 0.2% BSA (w/v) diluted in NATT buffer) for 2 h. After a further 90 min wash, the blots were subjected to ECL reagent and exposed to Kodak X-ray film.
###end p 17
###begin title 18
Immuno-precipitation
###end title 18
###begin p 19
For immuno-precipitation of TNFR1, equal amounts of pre-cleared cell lysates were incubated in Tris-HCl buffer, pH 7.4, containing 50 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% (w/v) Triton X-100, and 0.5% (w/v) Nonidet P-40, with 2 mug TNFR1 antibody, pre-coupled to protein G, for 3 h. Lysates were recovered by sequential washes in solubilisation buffer and in the same buffer lacking detergents. Precipitates were assessed for TRADD or RIP content using Western blotting.
###end p 19
###begin title 20
JNK activity assay
###end title 20
###begin p 21
###xml 247 248 247 248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 250 251 250 251 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 685 686 675 676 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 687 688 677 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 810 812 794 796 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
To measure JNK activity, cells were stimulated as appropriate and the reaction terminated by rapid aspiration and the addition of ice-cold PBS. The cells were solubilised in 20 mM HEPES buffer, pH 7.7, containing 50 mM NaCl, 0.1 mM EDTA, 0.1 mM Na3VO4, 0.1 mM PMSF, 10 mg/ml aprotinin, 10 mg/ml leupeptin, and 1% (w/v) Triton X-100. Lysates were clarified by centrifugation for 5 min at 13,000 rpm and equal amounts of protein were incubated with 20 mug of GST-c-Jun-(5-89) immobilized on glutathione-Sepharose at 4 degreesC for 3 h. Beads were then washed three times in solubilisation buffer and twice in 25 mM HEPES buffer, pH 7.6, containing 20 mM beta-glycerophosphate, 0.1 mM NaV3O4, and 2 mM dithiothreitol. Precipitates were then incubated with the same buffer containing 25 muM/0.5 muCi of ATP/[gamma-32P] ATP in a final volume of 30 microl at 30 degreesC for 30 min. The reactions were terminated by the addition of 4x SDS-sample buffer and aliquots of each sample subjected to electrophoresis on 11% SDS-polyacrylamide gel electrophoresis. Phosphorylation of GST-c-Jun was then determined by autoradiography.
###end p 21
###begin title 22
Statistical analysis
###end title 22
###begin p 23
###xml 199 200 197 198 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 211 212 209 210 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Where experimental data is shown as a blot, this represents one of at least 3 experiments and data represents the mean +/- s.e.m. Statistical analysis was by one-way ANOVA with Dunnett's post test (*P < 0.05, **P < 0.01).
###end p 23
###begin title 24
Results
###end title 24
###begin p 25
###xml 72 73 72 73 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 379 387 371 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 411 417 403 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig1" ref-type="fig">Fig.&#160;1</xref>
###xml 488 489 480 481 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 479 484 <span type="species:ncbi:9606">human</span>
Initially we sought to investigate the potential for synergy between PAR2 and TNFalpha receptor subtypes by a combination of different pre-incubation strategies. However no noticeable synergy was observed; rather when cells were pre-incubated with trypsin for 30 min we revealed a concentration-dependent inhibition of subsequent TNFalpha-stimulated JNK activity, as measured by in vitro c-Jun phosphorylation (Fig. 1, Panels A and B). This inhibitory effect was mimicked by the human PAR2 tethered ligand agonist SLIGKV-OH and was reflected at the level of phospho-JNK confirming inhibition of JNK phosphorylation rather than JNK activity itself (Panel C).
###end p 25
###begin p 26
###xml 56 62 52 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
###xml 381 387 357 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig2" ref-type="fig">Fig.&#160;2</xref>
Inhibition of TNFalpha signalling was pathway specific (Fig. 2), as no equivalent inhibition of p38 MAP kinase was observed following SLIGKV-OH pre-treatment (Panel A) whilst ERK activation in response to TNFalpha was negligible in this cell type (data not shown). However, TNFalpha-induced loss in IkappaBalpha expression, a marker of NFkappaB activation, was partially reversed (Fig. 2, Panel B).
###end p 26
###begin p 27
###xml 34 35 34 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 137 143 133 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig3" ref-type="fig">Fig.&#160;3</xref>
###xml 382 383 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 470 471 466 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 538 539 534 535 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 737 738 733 734 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 461 466 <span type="species:ncbi:9606">human</span>
We next sought to confirm that PAR2 was indeed required for tryspin and peptide mediated inhibition of TNFalpha-mediated JNK signalling (Fig. 3). Using either parental NCTC2544 or vector expressing cells (not shown) we found no equivalent inhibition of JNK activity (Panel A) at any concentration of peptide tested. Secondly, we found that pre-incubation of cells with the novel PAR2 antagonist K-14585 was able to reverse the inhibition of JNK mediated by the human PAR2 activating peptide SLIGKV-OH (Panel B). Another candidate PAR, PAR4 expressed in the same cell type was without effect confirming the receptor specificity of the response (Panel C). Panel D illustrates that this inhibition is a feature of endogenously expressed PAR2, as pre-treatment of HUVECs with peptide reduced TNFalpha-stimulated JNK phosphorylation. Interestingly, P2Y2 stimulation mediated greater inhibition of TNFalpha stimulated JNK signalling, suggesting that other GPCRs exhibit the same phenomenon.
###end p 27
###begin p 28
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 194 200 194 200 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib8 bib28" ref-type="bibr">[8,28]</xref>
###xml 313 315 309 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 431 437 419 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig4" ref-type="fig">Fig.&#160;4</xref>
###xml 558 562 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib28" ref-type="bibr">[28]</xref>
###xml 765 767 753 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 950 952 930 932 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
In addition, we further analysed the concentration dependency of not only SLIGKV-OH but also the substituted peptide 2f-LIGKV-OH originally identified by ourselves as a more potent PAR2 agonist [8,28]. Both peptides profoundly inhibited TNFalpha-stimulated JNK activity in a concentration-dependent manner with IC50 values of 6 muM (6.24 +/- 1.319 muM) for SLIGKV-OH and approximately 2 muM (1.582 +/- 0.3422 muM) for 2f-LIGKV-OH (Fig. 4, Panel A). This accords well with the potency of these peptides assessed in a series of assays using the same cell line [28]. However, we also found that these peptides alone were able to stimulate JNK activity in a concentration-dependent manner (Panel B). For example, 2f-LIGKV-OH caused a strong activation of JNK with an EC50 value of 2 muM (2.121 +/- 0.4041 muM), similar to its ability to inhibit JNK stimulation in response to TNFalpha. In contrast, SLIGKV-OH was a less potent activator of JNK with an EC50 value of approximately 10 muM (10.12 +/- 3.305 muM) in comparison to its ability to inhibit JNK (Panel C). Moreover, the difference in efficacy was marked, and SLIGKV-OH behaved as a full agonist in inhibiting TNFalpha signalling (% inhibition = 93.567 +/- 6.882%) but was a partial agonist in stimulating JNK activity alone (% stimulation = 43.950 +/- 6.482%).
###end p 28
###begin p 29
###xml 105 106 105 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 279 280 279 280 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 455 461 455 461 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig5" ref-type="fig">Fig.&#160;5</xref>
###xml 542 543 542 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We then examined the potential signalling pathways which could be mediating the inhibitory effects of PAR2. PAR2 is coupled to a number of signalling pathways via G-protein dependent and independent mechanisms. Initially, we found that we could mimic the inhibitory effect of PAR2 activation with PMA and that this effect could be reversed by micromolar concentrations of the PKC inhibitor, GF109203X, thereby implicating the involvement of PKC isoforms (Fig. 5, Panel A). Therefore, we tested the effect of the PKC inhibitor GF109203X on PAR2 mediated inhibition of JNK activity and phosphorylation. Pre-incubation with a maximal concentration (10 muM) of this inhibitor reversed the inhibitory effect of trypsin and SLIGKV-OH on TNFalpha-stimulated JNK activation (Panel B and C) and phosphorylation (Panel D). In contrast, another inhibitor Go6976 which preferentially inhibits the classical group of PKC isoforms was without effect (not shown) suggesting a potential role for the novel PKC isoforms.
###end p 29
###begin p 30
###xml 35 39 31 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 50 51 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 80 86 76 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig6" ref-type="fig">Fig.&#160;6</xref>
###xml 111 115 103 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 226 230 218 222 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 662 663 646 647 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We then examined the role of Galphaq/11 in the PAR2 mediated inhibitory effect (Fig. 6), using the novel Galphaq/11 inhibitor YM254890. This compound has been used previously in our laboratory and has been validated elsewhere [29]. In untreated cells, TNFalpha stimulated JNK phosphorylation and activity as expected, and this was inhibited by the pre-treatment with SLIGKV-OH. However pre-treatment of the cells with YM254890 resulted in almost complete abrogation of peptide mediated inhibition of TNFalpha stimulated JNK phosphorylation (Panel A) and activity (Panels B and C). A similar reversal was also observed in HUVECs (panel D) although the initial PAR2 mediated inhibition was less.
###end p 30
###begin p 31
###xml 121 122 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 578 579 566 567 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 603 608 591 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="fig7" ref-type="fig">Fig&#160;7</xref>
###xml 734 735 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 806 807 794 795 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We next examined the potential site of inhibition within the TNFalpha-mediated cascade. We assessed the potential for PAR2 activation to disrupt the interaction of TNFR1 with a number of associated proteins. TNFR1 was precipitated and the interaction with other proteins assessed by Western blotting. In basal conditions binding to TRADD and RIP was minimal, however, following stimulation with TNFalpha there was a marked increase in both TRADD and RIP recovery confirming the formation of a TNFalpha-sensitive complex. Formation of this complex was severely disrupted with PAR2 peptide pre-treatment (Fig 7, Panel A). Using the TNFR1/TRADD interaction as a model we pre-incubated cells with either GF109203X or YM254890 prior to PAR2 activating peptide pre-treatment. Both agents effectively reversed PAR2 mediated disruption of TNFalpha driven TNFR1 and TRADD complex formation (Panel B).
###end p 31
###begin title 32
Discussion
###end title 32
###begin p 33
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 130 134 126 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 277 278 273 274 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
This study identifies a novel paradigm for PAR2 inhibition of TNFalpha-induced JNK signalling. Our evidence strongly points to a Gq/11 and PKC-dependent cascade which functions to disrupt TNFR1 dependent signalling. Significantly, this inhibitory phenomenon is a feature of PAR2 in cells endogenously expressing the receptor and in response to activation of other GPCRs, namely P2Y2 receptors. Thus, it may have implications as to the regulatory role of GPCRs in a number of physiological and pathophysiological conditions.
###end p 33
###begin p 34
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 264 265 260 261 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 308 312 304 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib26" ref-type="bibr">[26]</xref>
###xml 513 517 509 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib30" ref-type="bibr">[30]</xref>
###xml 630 634 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib31" ref-type="bibr">[31]</xref>
###xml 708 712 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib32" ref-type="bibr">[32]</xref>
###xml 869 870 865 866 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1088 1089 1084 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1208 1209 1200 1201 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1362 1363 1350 1351 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1508 1509 1496 1497 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1566 1570 1554 1558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
Initially, we sought to assess the potential of synergy between PAR2 activation and other cytokines known to participate in inflammation such as TNFalpha, IL-1 and LPS through activation of selective TLRs. Indeed a recent study has demonstrated synergy between PAR2 and TLR-4 through the activation of Myd88 [26], and a synergistic effect between the PAR-2 and LPS receptor, was also previously demonstrated where PAR agonists and LPS in combination potentiated the synthesis of IL-8 from airway epithelial cells [30]. However while research to date has shown the possibility of receptor cross talk between the PAR family members [31] and with other GPCRs such as the epidermal growth factor receptor (EGFR) [32] few studies have looked at possible interactions with other receptors, such as cytokine, chemokine and other inflammatory receptors. Since activation of PAR2 exhibits many features similar to cytokines regarding the activation of inflammatory mediator release, this study sought to characterise the differences and similarities of the signalling pathways mediated by both PAR2 and TNFalpha, and to examine the possibility of synergy between these two receptors. To our surprise we found that PAR2 activation was able to strongly mediate an inhibition of TNFalpha mediated JNK signalling in response to cellular activation by trypsin suggesting a PAR2 mediated response. Indeed the inhibitory effect of trypsin was mimicked with the peptides SLIGKV-OH and 2f-LIGKV-OH, but reversed by a novel PAR2 antagonist K14858, which we have recently characterised [33].
###end p 34
###begin p 35
###xml 106 107 106 107 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 188 189 188 189 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 229 233 229 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib17" ref-type="bibr">[17]</xref>
###xml 807 811 800 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib34" ref-type="bibr">[34]</xref>
###xml 914 915 907 908 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 915 922 908 915 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib35 bib36" ref-type="bibr">[35,36]</xref>
Our pharmacological studies also revealed the potential for agonist-mediated signalling in relation to PAR2 and JNK. We have previously demonstrated that trypsin mediated activation of PAR2 results in an increase in JNK activity [17] and indeed alone SLIGKV-OH and 2fl-LIGKV-OH were able to increase JNK. However, we also found a distinct profile in the ability of SLIGKV-OH to inhibit TNFalpha mediated JNK and to activate JNK alone, it was less potent and efficacious in the latter assay. Thus, we can discern two agonist-mediated directed events which relate to the activation of JNK. This type of modality is emerging for GPCRs for example the beta2 antagonist propranolol, whilst being an inverse agonist at the level of cAMP accumulation, functions as a partial agonist at the level of ERK activation [34]. Similar types of dual coupling to ERK and other intermediates have recently been demonstrated for PAR2[35,36] but not due to agonist specific differences.
###end p 35
###begin p 36
###xml 206 207 206 207 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 227 231 227 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib33" ref-type="bibr">[33]</xref>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 464 468 460 464 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib37" ref-type="bibr">[37]</xref>
###xml 601 605 597 601 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 815 820 800 805 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12/13</sub>
###xml 880 884 865 869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib38" ref-type="bibr">[38]</xref>
###xml 892 894 873 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12</sub>
###xml 977 981 958 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib39" ref-type="bibr">[39]</xref>
Whilst this present study focuses on two agonist effects it is the first study to raise this potential when examining JNK activation. This model was also supported when examining the effect of the novel PAR2 antagonist K-14585 [33]. Whilst in this present study we show that K-14585 is able to reverse PAR2 mediated inhibition of TNFalpha signalling, we found that at higher concentrations, K14585 alone is able to activate both JNK (not shown) and p38 MAP kinase [37]. Taken together, these findings indicate two distinct agonist-directed signalling pathways driven by SLIGKV-OH, one dependent upon Gq/11 and one independent, mediating inhibition and activation of JNK respectively. Studies assessing JNK activation in response to GPCRs are limited; however, it has been shown that free betagamma dimers and Galpha12/13 subunits can activate JNK in a Rac1-cdc42 dependent manner [38]. Galpha12 can also activate JNK via ASK1, independently of the activation of Rac1 and cdc42 [39].
###end p 36
###begin p 37
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 244 245 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 337 338 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 411 413 411 413 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 452 459 452 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib40 bib41 bib42" ref-type="bibr">[40&#8211;42]</xref>
###xml 473 474 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 645 649 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib43" ref-type="bibr">[43]</xref>
###xml 1035 1036 984 985 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1162 1169 1111 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib44 bib45" ref-type="bibr">[44,45]</xref>
###xml 1224 1225 1173 1174 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1093 1097 <span type="species:ncbi:10116">rats</span>
###xml 1102 1106 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
We then sought to investigate the possible mechanisms by which PAR2 mediated inhibition of JNK might occur. Our initial studies indicated that DAG-dependent PKC isoforms are involved in the response since PMA was able to mimic the effect of PAR2 activation, abolishing both JNK activity and phosphorylation. We found good reversal of PAR2 mediated inhibition using GF109203X, an inhibitor known to block both Ca2+-dependent and some novel PKC isoforms [40-42]. NCTC2544-PAR2 cells were found to express the PKC isoforms, PKCalpha, beta11, delta, epsilon and theta. This is typical of a number of keratinocyte cell types including NHEK and HaCat [43]. Previously, we have shown that PKCalpha and PKCdelta play a role in regulating NFkappaB signalling at the level of both IKK activation and phosphorylation of p65 NFkappaB, however equivalent studies here using siRNA for PKCalpha, epsilon and theta have not revealed a specific isoform to date responsible for JNK inhibition (not shown). PKC is also implicated in a number of other PAR2-mediated events including sensitization of the TRPV1 in rats and mice, and chloride transport in intestinal epithelial cells [44,45] and this current study extends the role for PKC in PAR2-dependent signalling events.
###end p 37
###begin p 38
###xml 49 53 49 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 120 124 120 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 337 338 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 388 392 388 392 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 533 537 529 533 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 584 585 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 649 653 641 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 704 705 696 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 808 812 796 800 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 834 835 822 823 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 951 952 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1222 1223 1178 1179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1238 1242 1190 1194 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib29" ref-type="bibr">[29]</xref>
###xml 1270 1271 1222 1223 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Our studies also revealed an important role for Gq/11 in PAR2 mediated inhibition of JNK signalling. We used the novel Gq/11 inhibitory compound YM254890 which we have previously shown to be a very effective inhibitor of trypsin and peptide mediated [3H]IP accumulation [29]. In the present study we demonstrated complete reversal of PAR2 mediated JNK inhibition. Thus, DAG derived from Gq/11 activation is likely to drive PKC activation and subsequent inhibition of TNFalpha stimulated JNK activity. Previously, we have shown that Gq/11 plays a positive role in the regulation of PAR2 mediated NFkappaB phosphorylation and in DNA reporter activity [29], whilst other groups have clearly demonstrated PAR2 coupling to NFkappaB. Thus, these findings conflict with this present study showing the potential of Gq/11 to play a role in PAR2 mediated inhibition of TNFalpha stimulated IkappaBalpha loss. Interestingly, whilst we were able to demonstrate PAR2 mediated inhibition of TNFalpha induced IkappaBalpha loss this effect was not manifest further downstream, and pre-treatment of cells with peptide did not inhibit subsequent TNFalpha-stimulated NFkappaB reporter activity. Thus, because of the strong interactions of PAR2 with NFkappaB [29], the overall outcome of PAR2/TNFR1 is a loss in JNK activation only. We are currently assessing if receptors more poorly coupled to NFkappaB, for example P2Y2, can mediate an overall inhibition of NFkappaB activation.
###end p 38
###begin p 39
###xml 230 234 230 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib46" ref-type="bibr">[46]</xref>
###xml 672 679 660 667 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib47 bib48 bib49" ref-type="bibr">[47&#8211;49]</xref>
###xml 980 984 968 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib46" ref-type="bibr">[46]</xref>
###xml 1103 1110 1091 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rid="bib42 bib50" ref-type="bibr">[42,50]</xref>
###xml 1259 1260 1247 1248 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1262 1266 1250 1254 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 1334 1335 1322 1323 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We also demonstrate for the first time receptor mediated driven disruption of TNFR1 binding to a number of associated proteins. Upon activation TNFR1 associates with a number of proteins including TRADD, RIP, TRAF2, MADD and FADD [46]. Formation of this complex at the membrane allows TNFalpha to mediate an array of different signalling events, such as induction of apoptosis through the FADD-caspase arm or activation of MAP kinase and NFkappaB signalling via TRAF2. For example, TRAF2 contains a conserved C-terminal region termed the TRAF domain, which interacts with TRADD and an N-terminal ring finger required for signalling the activation of NFkappaB and JNK/SAPK [47-49]. The fact that p38 MAP kinase was not inhibited suggests a point in the pathway upstream of both NFkB and JNK. This is likely to be at the level of TRAFs or MEKKs such as TAK1 or ASK1, however this will be difficult to decipher as less is known about TRAF mediated activation of the p38 MAPK pathway [46]. Two recent studies have shown the potential of PMA, a PKC activator, to disrupt TNFR1 binding to these intermediates [42,50], however the study presented here is the first to show that this can be receptor mediated. Pharmacological experiments also demonstrate that the PAR2/Gq/11/PKC axis is essential in driving such disruption in response to PAR2. At this point the exact mechanism mediating disruption is unclear, no studies to date have identified any PKC phosphorylation sites within the TNFR1 complex, and thus it is possible that additional intermediate proteins may be involved.
###end p 39
###begin p 40
###xml 174 175 170 171 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 283 284 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The potential for GPCRs to mediate the inhibition of TNFalpha-mediated JNK signalling has clear physiological significance. For example, in the endothelium, activation of PAR2 would be able to reduce the damaging effects of TNFalpha during inflammation. In other cell types where PAR2 is expressed inhibition of TNFR1 signalling may be of significance in relation to cancer.
###end p 40
###begin title 41
Conclusions
###end title 41
###begin p 42
###xml 83 84 83 84 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In conclusion we have demonstrated for the first time a novel mechanism whereby PAR2, a GPCR can disrupt TNFalpha mediated activation of the JNK pathway. This will provide valuable information regarding the role of GPCRs in the context of inflammation and other disease states.
###end p 42
###begin p 43
###xml 16 18 16 18 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1.</label>
###xml 21 22 21 22 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 123 115 119 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 18 124 18 120 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="44">PAR<sub>2</sub> mediated inhibition of TNF&#945; activated JNK is via coupling to the heterotrimeric G-protein, G<sub>q/11</sub>.</p>
###xml 16 124 16 120 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>1.</label><p textid="44">PAR<sub>2</sub> mediated inhibition of TNF&#945; activated JNK is via coupling to the heterotrimeric G-protein, G<sub>q/11</sub>.</p></list-item>
###xml 124 126 120 122 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2.</label>
###xml 126 299 122 295 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="45">This inhibitory response requires members of the PKC family, and inhibits TNF activation of JNK by disrupting coupling of accessory proteins, such as RIP and TRADD to TNFR1.</p>
###xml 124 299 120 295 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>2.</label><p textid="45">This inhibitory response requires members of the PKC family, and inhibits TNF activation of JNK by disrupting coupling of accessory proteins, such as RIP and TRADD to TNFR1.</p></list-item>
###xml 299 301 295 297 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3.</label>
###xml 351 355 343 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 301 405 297 397 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="46">This inhibitory effect is mediated by other G&#945;<sub>q/11</sub> linked GPCRs, in particular by the P2Y2 receptor.</p>
###xml 299 405 295 397 <list-item xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><label>3.</label><p textid="46">This inhibitory effect is mediated by other G&#945;<sub>q/11</sub> linked GPCRs, in particular by the P2Y2 receptor.</p></list-item>
###xml 16 405 16 397 <list xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" list-type="simple"><list-item><label>1.</label><p textid="44">PAR<sub>2</sub> mediated inhibition of TNF&#945; activated JNK is via coupling to the heterotrimeric G-protein, G<sub>q/11</sub>.</p></list-item><list-item><label>2.</label><p textid="45">This inhibitory response requires members of the PKC family, and inhibits TNF activation of JNK by disrupting coupling of accessory proteins, such as RIP and TRADD to TNFR1.</p></list-item><list-item><label>3.</label><p textid="46">This inhibitory effect is mediated by other G&#945;<sub>q/11</sub> linked GPCRs, in particular by the P2Y2 receptor.</p></list-item></list>
Specific points:1.PAR2 mediated inhibition of TNFalpha activated JNK is via coupling to the heterotrimeric G-protein, Gq/11.2.This inhibitory response requires members of the PKC family, and inhibits TNF activation of JNK by disrupting coupling of accessory proteins, such as RIP and TRADD to TNFR1.3.This inhibitory effect is mediated by other Galphaq/11 linked GPCRs, in particular by the P2Y2 receptor.
###end p 43
###begin p 44
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 101 105 97 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
PAR2 mediated inhibition of TNFalpha activated JNK is via coupling to the heterotrimeric G-protein, Gq/11.
###end p 44
###begin p 45
This inhibitory response requires members of the PKC family, and inhibits TNF activation of JNK by disrupting coupling of accessory proteins, such as RIP and TRADD to TNFR1.
###end p 45
###begin p 46
###xml 50 54 46 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
This inhibitory effect is mediated by other Galphaq/11 linked GPCRs, in particular by the P2Y2 receptor.
###end p 46
###begin title 47
Acknowledgements
###end title 47
###begin p 48
This work was sponsored by the Wellcome Trust (RP).
###end p 48
###begin p 49
YM254890 was a kind gift from Astellas Pharma.Inc, Japan. TNFR1 and TRADD antibodies were a kind gift of Professor David McEwan (UEA). Kathryn McIntosh was a recipient of a Paisley University PhD studentship award.
###end p 49
###begin title 50
References
###end title 50
###begin p 51
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 98 99 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 119 120 115 116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 590 591 580 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 602 603 592 593 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
PAR2 activation mediates inhibition of TNFalpha-stimulated JNK activity and phosphorylation in PAR2 NCTC2544 cells. PAR2 expressing NCTC2544 cells (clone G) were pre-incubated with increasing concentrations of trypsin or SLIGKV-OH for 30 min prior to stimulation for a further 30 min with TNFalpha (+) (10 ng/ml). Samples were assessed for JNK activity (Panel A) or phospho-JNK levels (Panel C) as outlined in the Methods section. Gels from JNK assays were quantified (Panel B). Each value represents the mean +/- s.e.m from at least 4 experiments and data was quantified by densitometry. ⁎P < 0.05, ⁎⁎P < 0.01 compared to TNFalpha alone.
###end p 51
###begin p 52
###xml 106 107 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The effect of SLIGKV-OH upon TNFalpha-stimulated p38 MAP kinase phosphorylation and IkappaBalpha loss. PAR2 expressing NCTC2544 cells (clone G) were pre-incubated with increasing concentrations of SLIGKV-OH for 30 min prior to stimulation for a further 30 min with TNFalpha (+) (10 ng/ml). Samples were assessed for phospho-p38 MAP kinase activity (Panel A) or IkappaBalpha levels (Panel B) as outlined in the Methods section. Each gel is representative of at least 4 experiments.
###end p 52
###begin p 53
###xml 68 69 64 65 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 274 275 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 438 439 424 425 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
Inhibition of TNFalpha-stimulated JNK activity is dependent upon PAR2 activation. In Panel A, parental NCTC2544 cells were pre-incubated with increasing concentrations of trypsin, 30 min prior to stimulation for a further 30 min with TNFalpha (+) (10 ng/ml). In Panel B, PAR2 NCTC2544 cells were pre-incubated with 10 muM K14585 for 30 min prior to addition of SLIGKV-OH (100 muM) for 30 min and stimulation with TNFalpha. In Panel C, PAR4 expressing cells were incubated with AYPGKF (100 microM) 30 min prior to TNFalpha stimulation. In Panel D, HUVECs were treated with either SLIGKV-OH (SLIG) or 50 muM UTP for 30 min prior to TNFalpha stimulation. Samples were assessed for JNK activity or phospho-JNK content as outlined in the Methods section. Each gel is representative of at least 3 experiments.
###end p 53
###begin p 54
###xml 37 38 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 116 117 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Concentration response effects of PAR2 peptides for activation of JNK and inhibition of TNFalpha-stimulated JNK. PAR2 expressing NCTC2544 cells (clone G) were incubated with increasing concentrations of SLIGKV-OH or 2f-LIGKV-OH for 30 min and assayed for JNK activity (Panel B) or stimulated for a further 30 min with TNFalpha (+) before JNK activity was assessed (Panel A). Samples were assessed for JNK activity as outlined in the Methods section. Gels from JNK assays were quantified (Panel C). Each value represents the mean +/- s.e.m from at least 4 experiments and data was quantified by densitometry.
###end p 54
###begin p 55
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 121 122 117 118 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 668 669 658 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Pharmacological blockade of protein kinase C reverses PAR2 mediated inhibition of TNFalpha-stimulated JNK activation. PAR2 expressing NCTC2544 cells (clone G) were pre-incubated with increasing concentrations of GF109203X (GFX) for 30 min then incubated for a further 30 min with 100 nM PMA (Panel A) or 30 nM trypsin (Panel B) prior to stimulation for a further 30 min with TNFalpha(+) (10 ng/ml). Samples were assessed for JNK activity (Panels A and B) or phospho-JNK levels (Panel D) as outlined in the Methods section. Gels from JNK activity assays were quantified by densitometry (Panel C). Each value represents the mean +/- s.e.m from at least 4 experiments. ⁎⁎P < 0.01 compared to TNFalpha and trypsin stimulated.
###end p 55
###begin p 56
###xml 1 5 1 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">q/11</sub>
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 82 83 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 646 647 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Gq/11 is essential for PAR2 mediated inhibition of JNK activation by TNFalpha. PAR2 expressing NCTC2544 cells (Panels A and B) or HUVECs (Panel D) were pre-incubated with (100 nM - Panel A) increasing concentrations of YM254890 (YM) for 30 min then incubated for a further 30 min with SLIGKV-OH (100 muM) prior to stimulation for a further 30 min with TNFalpha (+) (10 ng/ml). Samples were assessed for phospho-JNK levels (Panels A and D) or JNK activity (Panel B) as outlined in the Methods section. Gels from JNK activity assays were quantified by densitometry (Panel C). Each value represents the mean +/- s.e.m from at least 4 experiments. ⁎⁎P < 0.01 compared to TNFalpha and peptide stimulated.
###end p 56
###begin p 57
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
PAR2 mediated TNFR1 adapter protein disruption in PAR2 expressing cells. In Panel A, cells were pre-treated with peptide (100 muM) or vehicle prior to stimulation with TNFalpha (10 ng/ml) for 30 min. Lysates were immuno-precipitated for TNFR1 and immuno-blotted for TRADD and/or RIP, as outlined in the Methods section. In Panel B cells were pre-treated with 100 nM YM254890 or 3 muM GF109203X for 30 min prior to pre-treatment with peptide (100 muM), for 30 min, then incubated for a further 30 min with TNFalpha (10 ng/ml). TNFR1 immuno-precipitates were immuno-blotted for TRADD. Each gel is representative of at least three experiments.
###end p 57

